FHL2 binds calcineurin and represses pathological cardiac growth

Berdymammet Hojayev1, Beverly A Rothermel, Thomas G Gillette

  • 1Department of Internal Medicine (Cardiology), University of Texas Southwestern Medical Center, Dallas, TX, USA.

Insights

Four-and-a-half LIM domain protein 2 (FHL2) suppresses stress-induced calcineurin activation in the heart. FHL2 deficiency exacerbates cardiac hypertrophy and dysfunction, highlighting its protective role against heart failure.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Cellular Signaling

Background:

  • Stress-induced cardiac hypertrophy predisposes the heart to arrhythmia, contractile dysfunction, and heart failure.
  • Four-and-a-half LIM domain protein 2 (FHL2) is primarily expressed in the heart and its deficiency leads to heightened responses to adrenergic stress.
  • Calcineurin activation, downstream of β-adrenergic signaling, is crucial for stress-induced myocardial hypertrophy.

Purpose of the Study:

  • To investigate the hypothesis that FHL2 suppresses stress-induced calcineurin activation.
  • To elucidate the role of FHL2 in regulating cardiac responses to adrenergic stress and hypertrophy.

Main Methods:

  • In vivo studies using FHL2 knockout mice and isoproterenol stimulation to assess NFAT target gene expression.
  • In vitro studies using HEK 293 cells and neonatal rat ventricular myocytes (NRVMs) with reporter gene assays to evaluate FHL2's effect on calcineurin/NFAT signaling.
  • siRNA-mediated knockdown and overexpression of FHL2 to determine its functional role.
  • Immunostaining in adult cardiomyocytes to examine FHL2 and calcineurin localization and interaction.

Main Results:

  • FHL2 knockout mice exhibited amplified isoproterenol-induced increases in NFAT target genes RCAN1.4 and BNP.
  • FHL2 knockdown enhanced calcineurin/NFAT promoter activity, while FHL2 overexpression inhibited it.
  • FHL2 overexpression in NRVMs reduced hypertrophic growth in response to calcineurin activation.
  • FHL2 and calcineurin colocalized in cardiomyocytes, and their interaction was facilitated by endothelin-1.

Conclusions:

  • FHL2 acts as an endogenous suppressor of calcineurin activity in the heart.
  • FHL2 plays a critical role in mitigating stress-induced cardiac hypertrophy and dysfunction.
  • Targeting FHL2 may offer a therapeutic strategy for preventing or treating heart failure.

Related Concept Videos

Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Synthesis and Functions of Calcitonin00:51

Synthesis and Functions of Calcitonin

Calcitonin, a vital polypeptide hormone, regulates calcium levels within body fluids. It is released by the parafollicular cells, also known as C cells, situated in the follicular epithelium of the thyroid gland. Calcitonin responds to fluctuations in blood calcium levels and the influence of gastrointestinal hormones like gastrin and cholecystokinin.
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...